India, March 18 -- Researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center, have developed a new treatment for glioblastoma (GBM), the most aggressive type of brain cancer, which shows potential to reduce tumors in the short term.
The therapy targets two brain tumor-associated proteins instead of one, which has shown promise in reducing solid tumor growth in patients with recurrent GBM.
Two early clinical trials were conducted, which examined the safety and efficacy of CAR T-cell therapy.
In one trial, described in a paper published in the New England Journal of Medicine (NEJM), three patients with recurrent GBM participated, who had previously undergone standard radia...